Ingevity (NYSE:NGVT) Cut to Hold at Wall Street Zen

Key Points

• Wall Street Zen downgraded Ingevity from "buy" to "hold"; overall analyst mix is mixed (2 Buy, 2 Hold, 1 Sell) with a consensus target price of $80.00.
• Ingevity missed quarterly expectations, reporting $0.58 EPS vs. $0.74 expected and $255.1M revenue (down 3.2% y/y), and set FY2026 guidance of $4.80–$5.20 EPS versus analyst estimates around $4.45.
• The shares trade near $71.15 with a market cap of $2.51B and a 52‑week range of $28.49–$77.46, while institutional investors own roughly 91.6% of the stock.

Ingevity (NYSE:NGVT - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a report released on Saturday.

NGVT has been the topic of a number of other research reports. Zacks Research raised shares of Ingevity to a "hold" rating in a report on Tuesday, December 16th. Wells Fargo & Company boosted their target price on shares of Ingevity from $65.00 to $75.00 and gave the stock an "equal weight" rating in a research note on Friday, February 27th. BMO Capital Markets reiterated an "outperform" rating and set a $83.00 target price on shares of Ingevity in a research report on Monday, March 2nd. Jefferies Financial Group reissued a "buy" rating and set a $82.00 price target on shares of Ingevity in a research note on Thursday, February 26th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Ingevity in a report on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Ingevity has an average rating of "Hold" and a consensus target price of $80.00.

Ingevity Trading Up 0.1%

Shares of NGVT opened at $71.15 on Friday. The company has a debt-to-equity ratio of 39.10, a quick ratio of 0.79 and a current ratio of 1.33. The company has a market cap of $2.51 billion, a price-to-earnings ratio of -15.30 and a beta of 1.27. The stock has a fifty day moving average price of $69.73 and a two-hundred day moving average price of $61.02. Ingevity has a 52-week low of $28.49 and a 52-week high of $77.46.

Ingevity (NYSE:NGVT - Get Free Report) last announced its earnings results on Wednesday, February 25th. The company reported $0.58 EPS for the quarter, missing the consensus estimate of $0.74 by ($0.16). Ingevity had a positive return on equity of 126.25% and a negative net margin of 13.51%.The business had revenue of $255.10 million for the quarter, compared to the consensus estimate of $257.27 million. During the same quarter in the previous year, the company posted $0.95 EPS. Ingevity's revenue for the quarter was down 3.2% on a year-over-year basis. Ingevity has set its FY 2026 guidance at 4.800-5.20 EPS. Analysts predict that Ingevity will post 4.45 EPS for the current fiscal year.

Institutional Trading of Ingevity

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Amalgamated Bank lifted its position in Ingevity by 1.7% during the 3rd quarter. Amalgamated Bank now owns 10,593 shares of the company's stock valued at $585,000 after purchasing an additional 180 shares during the period. Wealth Enhancement Advisory Services LLC grew its position in shares of Ingevity by 3.1% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 7,823 shares of the company's stock worth $418,000 after buying an additional 238 shares during the period. EverSource Wealth Advisors LLC grew its position in shares of Ingevity by 15.7% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 1,870 shares of the company's stock worth $103,000 after buying an additional 254 shares during the period. Advisory Services Network LLC raised its stake in shares of Ingevity by 4.4% during the third quarter. Advisory Services Network LLC now owns 6,947 shares of the company's stock worth $383,000 after buying an additional 293 shares during the last quarter. Finally, Amundi raised its stake in shares of Ingevity by 4.8% during the third quarter. Amundi now owns 6,626 shares of the company's stock worth $364,000 after buying an additional 302 shares during the last quarter. 91.59% of the stock is currently owned by institutional investors and hedge funds.

About Ingevity

Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.

The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.